New partners for NASH

Pharmas are loading up their NASH portfolios expecting that addressing the full disease spectrum will require combinations, though the field lacks the tools to sort the different mechanisms on offer strategically.

Meanwhile, at least three companies presenting at this year’s American Association for the Study of Liver Diseases (AASLD) meeting will have proof-of-concept data from new targets that could add to the clinical armamentarium and list of potential combination partners. ...